Nitric oxide inhalation - INOpulse - Bellerophon Therapeutics

Drug Profile

Nitric oxide inhalation - INOpulse - Bellerophon Therapeutics

Alternative Names: Inhaled nitric oxide - Bellerophon; inhaled NO; iNO- Bellerophon; Nitric oxide-INOpulse

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ikaria Holdings
  • Developer Bellerophon Therapeutics
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary arterial hypertension
  • Phase II Pulmonary hypertension

Most Recent Events

  • 18 May 2018 Updated efficacy data from a phase II trial in Pulmonary hypertension presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 10 May 2018 Ikaria Hldings and Bellerophon expand licensing agreement for Nitric oxide inhalation to include Interstitial lung diseases
  • 10 May 2018 Bellerophon plans a phase IIb trial for Pulmonary hypertension (associated with chronic obstructive pulmonary disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top